Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.

Nabeel KhanChinmay TrivediFaten AberraTyler PernesYu-Xiao Yang

Published in: Journal of Crohn's & colitis (2022)

In a nationwide cohort of stable IBD patients, administration of RZV was not associated with the risk of IBD flare within 90 days. These findings should motivate further use of this highly effective vaccine.

Keyphrases

patients with inflammatory bowel disease
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
ulcerative colitis